Fatigue in renal cell carcinoma: The hidden burden of current targeted therapies

Oncologist

Volumn 15, Issue 11, 2010, Pages 1135-1146

  Larkin, James M G ^a   Pyle, Lynda M ^a   Gore, Martin E ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Fatigue; Renal cell carcinoma; Targeted therapy

Indexed keywords

AFINITOR; ALPHA INTERFERON; ANTIANEMIC AGENT; AXITINIB; BEVACIZUMAB; EVEROLIMUS; INTERLEUKIN 2; METHYLPHENIDATE; MODAFINIL; PAZOPANIB; PLACEBO; PSYCHOSTIMULANT AGENT; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; VOTRIENT;

ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COUGHING; COUNSELING; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ENERGY CONSERVATION; FATIGUE; HUMAN; KIDNEY CARCINOMA; MONOTHERAPY; OVERALL SURVIVAL; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PSYCHOSOCIAL CARE; QUALITY OF LIFE; SIDE EFFECT; SIGNAL TRANSDUCTION; SLEEP THERAPY; SURVIVAL RATE; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CYTOKINES; FATIGUE; HUMANS; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 78649923028     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0078     Document Type: Article

References (68)

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Cancer-Related Fatigue, Version 1.2009. Available at http://www.nccn.org/professionals/physician_gls/PDF/fatigue.pdf, accessed February 19, 2010.
2. Ryan JL, Carroll JK, Ryan EP et al. Mechanisms of cancer-related fatigue. The Oncologist 2007;12(suppl 1):22-34.
3. Montoya L. Managing hematologic toxicities in the oncology patient. J In-fus Nurs 2007;30:168-172.
4. Malik UR, Makower DF, Wadler S. Interferon-mediated fatigue. Cancer 2001;92(6 suppl):1664-1668.
5. Torino F, Corsello SM, Longo R et al. Hypothyroidism related to tyrosine kinase inhibitors: An emerging toxic effect of targeted therapy. Nat Rev Clin Oncol 2009;6:219-228.
6. Iop A, Manfredi AM, Bonura S. Fatigue in cancer patients receiving chemotherapy: Ananalysisof published studies. Ann Oncol 2004;15:712-720.
7. Portenoy RK. Cancer-related fatigue: An immense problem. The Oncologist 2000;5:350-352.
8. National Cancer Institute. Common Toxicity Criteria (CTC), Version 2.0. Available at http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcv20_4-30-992.pdf, accessed February 19, 2010.
9. Conill C, Verger E, Salamero M. Performance status assessment in cancer patients. Cancer 1990;65:1864-1866.
10. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655.
11. Curt GA. The impact of fatigue on patients with cancer: Overview of FATIGUE 1 and 2. The Oncologist 2000;5(suppl 2):9-12.
12. Curt GA, Breitbart W, Cella D et al. Impact of cancer-related fatigue on the lives of patients: New findings from the Fatigue Coalition. The Oncologist 2000;5:353-360.
13. Hutson TE, Figlin RA, Kuhn JG et al. Targeted therapies for metastatic renal cell carcinoma: An overview of toxicity and dosing strategies. The Oncologist 2008;13:1084-1096.
14. Cella D, Peterman A, Passik S et al. Progress toward guidelines for the management of fatigue. Oncology (Williston Park) 1998;12:369-377.
15. Ahlberg K, Ekman T, Gaston-Johansson F et al. Assessment and management of cancer-related fatigue in adults. Lancet 2003;362:640-650.
16. Parkin DM, Bray F, Ferlay J et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
17. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996;335:865-875.
18. Nelson EC, Evans CP, Lara PN Jr. Renal cell carcinoma: Current status and emerging therapies. Cancer Treat Rev 2007;33:299-313.
19. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Kidney Cancer, Version 2.2010. Available at http://www.nccn.org/professionals/physician_gls/PDF/kidney.pdf, accessed February 19, 2010.
20. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-124.
21. Kroog GS, Motzer RJ. Systemic therapy for metastatic renal cell carcinoma. Urol Clin North Am 2008;35:687-701
22. Belldegrun AS, Klatte T, Shuch B et al. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): A benchmark for emerging targeted cancer therapies. Cancer 2008; 113:2457-2463.
23. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 2007;370:2103-2111.
24. Wyeth Pharmaceuticals. Torisel Summary of Product Characteristics. Available at http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000799/WC500039912.pdf, accessed February 19, 2010.
25. Novartis. Everolimus Summary of Product Characteristics. Available at http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001038/WC500022814.pdf, accessed February 19, 2010.
26. Roche Pharma AG. Avastin Summary of Product Characteristics. Available at http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000582/WC500029271.pdf, accessed February 19, 2010.
27. P fizer. Sutent Summary of Product Characteristics. Available at http://www.medicines.org.uk/emc/medicine/18531,accessed February 19, 2010.
28. Bayer Healthcare. Nexavar Summary of Product Characteristics. Available at http://www.medicines.org.uk/emc/document.aspx?documentid=18520&docType=SPC, accessed February 19, 2010.
29. GlaxoSmith Kline. Votrient. Full Prescribing Information. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022465lbl.pdf, accessed February 19, 2010.
30. Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-7109.
31. Minton O, Stone P. A systematic review of the scales used for the measurement of cancer-related fatigue (CRF). Ann Oncol 2009;20:17-25.
32. Mitchell SA. Cancer-related fatigue: State of the science. PM R 2010;2: 364-383.
33. Barsevick AM, Newhall T, Brown S. Management of cancer-related fatigue. Clin J Oncol Nurs 2008;12(5 suppl):21-25.
34. Launay-Vacher V, Deray G. Hypertension and proteinuria: A class-effect of antiangiogenic therapies. Anticancer Drugs 2009;20:81-82.
35. Karaman MW, Herrgard S, Treiber DK et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008;26:127-132.
36. Porta C, Szczylik C. Tolerability of first-line therapy for metastatic renal cell carcinoma. Cancer Treat Rev 2009;35:297-307.
37. Escudier B, Eisen T, Stadler WM et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the Phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27: 3312-3318.
38. Escudier BJ, Bellmunt J, Negrier S et al. Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-a2a (IFN) in metastatic renal cell carcinoma (mRCC). J Clin Oncol 2009;27(15 suppl):5020.
39. Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584-3590.
40. Rini BI, Halabi S, Rosenberg J et al. Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206. J Clin Oncol 2009;27:(18 suppl):LBA5019.
41. Dean GE, Spears L, Ferrell BR et al. Fatigue in patients with cancer receiving interferon alpha. Cancer Pract 1995;3:164-172.
42. Rini BI, Rathmell WK. Biological aspects and binding strategies of vascular endothelial growth factor in renal cell carcinoma. Clin Cancer Res 2007; 13:741s-746s.
43. Rini BI, Halabi S, Rosenberg JE et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008;26:5422-5428.
44. Melichar B, Koralewski P, Ravaud A et al. First-line bevacizumab combined with reduced dose interferon-«2a is active inpatients with metastatic renal cell carcinoma. Ann Oncol 2008;19:1470-1476.
45. Escudier B, Szczylik C, Hutson TE et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:1280-1289.
46. Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505-2512.
47. Cella D, Li JZ, Cappelleri JC et al. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: Results from a phase III randomized trial. J Clin Oncol 2008;26:3763-3769.
48. Cella D, Michaelson MD, Cappelleri JC et al. Quality of life (QOL) with sunitinib versus interferon-alfa (IFN-a) as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): Final results. J Clin Oncol 2009; 27:6529.
49. Fiedler W, Serve H, Döhner H et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005;105:986-993.
50. Faivre S, Delbaldo C, Vera K et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24:25-35.
51. Le Tourneau C, Raymond E, Faivre S. Sunitinib: A novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST). Ther Clin Risk Manag 2007;3:341-348.
52. Speca J, Yenser S, Creel P et al. Improving outcomes with novel therapies for patients with newly diagnosed renal cell carcinoma. Clin Genitourin Cancer 2006;5(suppl 1):S24-S30.
53. Wolter P, Beuselinck B, Pans S et al. Flare-up: An often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors. Acta Oncol 2009;48:621-624.
54. Liu G, Jeraj R, Perlman S et al. Pharmacodynamic study of FLT-PET imaging in patients treated with sunitinib. J Clin Oncol 2008;26:(15 suppl): 3515.
55. U.S. Food and Drug Administration. Pazopanib. Available at http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm187509.htm, accessed February 19, 2010.
56. Kumar R, Crouthamel MC, Rominger DH et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer 2009; 101:1717-1723.
57. Sonpavde G, Hutson TE. Pazopanib: A novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep 2007;9:115-119.
58. Hutson TE, Davis ID, Machiels JP, et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol 2010;28:475-480.
59. Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol 2010;28:1061-1068.
60. Kapoor A. Inhibition of mTOR in kidney cancer. Curr Oncol 2009; 16(suppl 1):S33-S39.
61. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-2281.
62. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-456.
63. Kay A, Motzer R, Figlin R et al. Updated data from a phase III randomized trial of everolimus (RAD001) versus PBO in metastatic renal cell carcinoma (mRCC) [abstract 278]. Presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium, Orlando, Florida, February 26-28, 2009.
64. Markman M. The dangers of "cross-trial" and "cross-retrospective experience" comparisons: Examples employing data in the peer-reviewed ovarian cancer literature. Cancer 2007;109:1929-1932.
65. U.S. National Institutes of Health. Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma (COM-PARZ). Available at http://clinicaltrials.gov/ct2/show/NCT00720941, accessed February 19, 2010.
66. U.S. National Institutes of Health. Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-Line and Second-Line Treatment of Patients With Metastatic Renal Cell Carcinoma (RECORD-3). Available at http://www.clinicaltrials.gov/ct2/show/NCT00903175?term=record-00903173&rank=00903172, accessed February 19, 2010.
67. U.S. National Institutes of Health. Temsirolimus Versus Sorafenib as Second-Line Therapy in Patients With Advanced RCC Who Have Failed First-Line Sunitinib. Available at http://clinicaltrials.gov/ct2/show/NCT00474786?term=temsirolimus+sorafenib&rank=00474785, accessed February 19, 2010.
68. U.S. NationalInstitutesofHealth. Axitinib(AG013736)asSecondLineTherapy for Metastatic Renal Cell Cancer. Available at http://clinicaltrials.gov/ct2/show/NCT00678392?term=axitinib+sorafenib&rank=00678392, accessed February 19, 2010.